92 related articles for article (PubMed ID: 22084895)
21. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
Vender R
J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
[TBL] [Abstract][Full Text] [Related]
22. Out-of-plan medication in Medicare Part D.
Roberto PN; Stuart B
Am J Manag Care; 2014 Sep; 20(9):743-8. PubMed ID: 25365749
[TBL] [Abstract][Full Text] [Related]
23. Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug members in a national health plan.
Xu Y; Viswanathan HN; Ward MA; Clay B; Adams JL; Stolshek BS; Kallich JD; Fine S; Saag KG
J Eval Clin Pract; 2013 Feb; 19(1):50-9. PubMed ID: 21914091
[TBL] [Abstract][Full Text] [Related]
24. Cost-related nonadherence in the Medicare program: the impact of Part D.
Kennedy JJ; Maciejewski M; Liu D; Blodgett E
Med Care; 2011 May; 49(5):522-6. PubMed ID: 21430574
[TBL] [Abstract][Full Text] [Related]
25. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter?
Curkendall S; Patel V; Gleeson M; Campbell RS; Zagari M; Dubois R
Arthritis Rheum; 2008 Oct; 59(10):1519-26. PubMed ID: 18821651
[TBL] [Abstract][Full Text] [Related]
26. Effects of reaching the drug benefit threshold on Medicare members' healthcare utilization during the first year of Medicare Part D.
Raebel MA; Delate T; Ellis JL; Bayliss EA
Med Care; 2008 Oct; 46(10):1116-22. PubMed ID: 18815534
[TBL] [Abstract][Full Text] [Related]
27. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis.
Halpern R; Agarwal S; Borton L; Oneacre K; Lopez-Bresnahan MV
Adv Ther; 2011 Sep; 28(9):761-75. PubMed ID: 21870169
[TBL] [Abstract][Full Text] [Related]
28. Understanding the Medicare Part D prescription program: partnerships for beneficiaries and health care professionals.
De Natale ML
Policy Polit Nurs Pract; 2007 Aug; 8(3):170-81. PubMed ID: 18178923
[TBL] [Abstract][Full Text] [Related]
29. Generic alendronate use among Medicare beneficiaries: are Part D data complete?
Yun H; Curtis JR; Saag K; Kilgore M; Muntner P; Smith W; Matthews R; Wright N; Morrisey MA; Delzell E
Pharmacoepidemiol Drug Saf; 2013 Jan; 22(1):55-63. PubMed ID: 23135758
[TBL] [Abstract][Full Text] [Related]
30. Medication use and adherence among elderly Medicare beneficiaries with diabetes enrolled in Part D and retiree health plans.
Stuart B; Simoni-Wastila L; Yin X; Davidoff A; Zuckerman IH; Doshi J
Med Care; 2011 May; 49(5):511-5. PubMed ID: 21422956
[TBL] [Abstract][Full Text] [Related]
31. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
Bonafede MM; Gandra SR; Fox KM; Wilson KL
J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
[TBL] [Abstract][Full Text] [Related]
32. The impact of insurance instability on children's access, utilization, and satisfaction with health care.
Cassedy A; Fairbrother G; Newacheck PW
Ambul Pediatr; 2008; 8(5):321-8. PubMed ID: 18922506
[TBL] [Abstract][Full Text] [Related]
33. Medicare prescription drug plan coverage of pharmacotherapies for opioid and alcohol dependence in WA.
Kennedy J; Dipzinski A; Roll J; Coyne J; Blodgett E
Drug Alcohol Depend; 2011 Apr; 114(2-3):201-6. PubMed ID: 21134724
[TBL] [Abstract][Full Text] [Related]
34. Assessment of drug consumption patterns for Medicare Part D patients.
Pedan A; Lu J; Varasteh LT
Am J Manag Care; 2009 May; 15(5):323-7. PubMed ID: 19435400
[TBL] [Abstract][Full Text] [Related]
35. National assessment of Medicare prescription plan coverage gaps among patients with atrial fibrillation in the US.
Kim MH; Lin J; Kreilick C
Adv Ther; 2009 Aug; 26(8):784-94. PubMed ID: 19690820
[TBL] [Abstract][Full Text] [Related]
36. Medicare program; Medicare prescription drug benefit. Final rule.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
[TBL] [Abstract][Full Text] [Related]
37. Children in the United States with discontinuous health insurance coverage.
Olson LM; Tang SF; Newacheck PW
N Engl J Med; 2005 Jul; 353(4):382-91. PubMed ID: 16049210
[TBL] [Abstract][Full Text] [Related]
38. Potential impact of Medicare Part D in the end-stage renal disease population.
St Peter WL
Adv Chronic Kidney Dis; 2008 Apr; 15(2):140-6. PubMed ID: 18334238
[TBL] [Abstract][Full Text] [Related]
39. Role of health insurance coverage in women's access to prescription medicines.
Ranji UR; Wyn R; Salganicoff A; Yu H
Womens Health Issues; 2007; 17(6):360-6. PubMed ID: 18042485
[TBL] [Abstract][Full Text] [Related]
40. Effects of coverage gap reform on adherence to diabetes medications.
Zeng F; Patel BV; Brunetti L
Am J Manag Care; 2013 Apr; 19(4):308-16. PubMed ID: 23725362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
